Phase I study of intratumoral injection of HF10, naturally occurring mutant of herpes simplex virus type 1

Phase 1

• Conditions: on-CNS malignant solid tumor

• Registration Number: JPRN-UMIN000007263
• Lead Sponsor: Mie University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

Not provided

Exclusion Criteria

1) Past history of severe hypersensitivity. 2) Positive for HBs antigen, HCV antibody or HIV antibody. 3) Experience of autoimmune disease requiring treatment during 6 months prior to consent. 4) Active multiple primary malignancy. 5) With lesions, such as visceral metastases or bone metastases, which need emergent therapies. 6) Use of anti-HSV drugs. 7) Use of steroids or immune-suppressive drugs. 8) Patients with severe complications. 9) Presence of central nervous system metastasis. 10) Lesion to be treated: high risk of bleeding. 11) Lesion to be treated: high risk of penetration or perforation. 12) Use of anti-platelet drugs or difficult to cessation of them. 13) Use of anticoagulant which is unsafe for intratumoral injection. 14) Pregnant or breastfeeding. 15) Patients who deny contraception during this study. 16) Any other cases that the attending doctor judges not appropriate to enroll to this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified